

Populations of Models Show Increased Arrhythmogenicity of the Hypertrophic Cardiomyopathy MYBPC3-c.772G>A Mutation

Eugenio Ricci¹, Fazeelat Mazhar¹, Alan Fabbri¹, Chiara Bartolucci¹, Stefano Severi¹

¹University of Bologna, Italy

Abstract

Several mutations can lead to hypertrophic cardiomyopathy (HCM), making it the most common genetic heart disease. Given the large heterogeneity of phenotypes shown by mutation carriers, robust patient stratification is still lacking, limiting treatment efficacy. In this work, we adopt a population of models approach to investigate the arrhythmic potential of the recently discovered MYBPC3-c.772G>A mutation, to provide an additional risk assessment tool. According to this objective, we built control and mutated populations of 10000 electro-mechanical models of single adult ventricular myocytes, randomizing 19 parameters (maximal conductances, kinetics and contractile element parameters) and calibrating them according to experimental data ranges. The mutation was modeled by applying ionic and contractile remodeling measured on patients myectomy samples. Different stimulation protocols were implemented to assess the influence on delayed after depolarizations and early-after depolarizations (EADs) inducibility. The results highlight a higher propensity of mutated cells in showing an arrhythmic behavior, with Ca^{2+} -related and K^+ currents parameters driving EADs susceptibility. In conclusion, this work provides detailed insights on HCM arrhythmia mechanisms, potentially aiding risk stratification of patients.

1. Introduction

Recent works [1, 2] have discovered a founder-effect mutation in the myosin-binding protein C3, involved in sarcomere organization and thus in cardiac contraction modulation. Experiments on both hiPSCs and adult myocytes obtained from patients myectomies have shown that the mutation determines faster cross-bridge cycling between myosin and actin filaments. However, this does not translate in an increased force generation due to the compensatory effect of electrophysiological remodeling. In particular, lower expression of repolarizing potassium channels, and slower Ca^{2+} -handling kinetics, balance the direct effect of the mutation. However, this 1) comes at

the cost of possible increased arrhythmic risk and 2) does not reduce the increased energy consumption given by faster contraction kinetics. Eventually, indeed, the mutation leads to a hypertrophic cardiomyopathy (HCM) phenotype in a population of patients from northeastern Tuscany, Italy. Previous works on sarcomeric mutations have highlighted how ion channel remodeling (mainly K^+ currents down-regulation as well as late sodium and L-type calcium currents up-regulation [3]) leads to increased susceptibility of single cells and tissues to arrhythmia [4, 5]. Here, we build on this to assess the electrophysiological effects of the MYBPC3-c.772G>A mutation. Using mathematical models and adopting a population approach, we evaluate possible increased arrhythmic risk markers given by this specific mutation.

2. Methods

2.1. Single cell model

For the simulations, we employed the "BPS-Land" adult ventricular myocyte model developed in our group [6]. The electrophysiological part is a development of the TorOrd model [7], able to reproduce the inversely proportional relationship between action potential duration and extracellular calcium concentration [8]. The contractile part is represented by the Land et al. model [9], allowing for fully coupled electro-mechanical feedback.

2.2. Population of models

Following the consolidated approaches adopted in our and other laboratories [4, 10], we generated a population of 10000 single cells using Latin hypercube sampling in the range $[-50\%, +200\%]$. We randomized 19 parameters: 11 maximal conductances and fluxes (g_{Na} , g_{NaL} , g_{K1} , g_{Kr} , g_{Ks} , g_{to} , g_{NaCa} , g_{NaK} , $J_{rel,max}$, $J_{up,max}$, P_{CaL}), 3 kinetics parameters (τ_f , τ_s , τ_{Ca} ; respectively the voltage-dependent fast and slow I_{CaL} time constants and the Ca^{2+} -dependent one) as well as 5 parameters of the contractile element (n_{perm} , $Ca_{50,TRPN}$, $Ktm_{unblock}$, mu , nu). Simulations lasted 200 s, and the last action

potential was analyzed. Action potential (*AP*), calcium transient (*CaT*) and active tension (*AT*) biomarkers were computed as in previous works [4, 6, 8]. Calibration was performed by accepting only the cells whose biomarkers fell within the experimental ranges (min, max). Since for active tension the latter were too restrictive to obtain a sufficient number of cells in the population, we used a cost function as in [11] to soften this requirement while preserving reliable biomarkers values.

2.3. Modeling the mutation

Model parameters were changed according to mutation-specific experimental reports [1] and unspecific HCM remodeling from previous computational studies [5]. Semi-automatic parameter optimization (based on a gradient-descent approach) was adopted to better constrict the changes based on weaker data sources (e.g. mRNA expression instead of patch-clamp recordings). Changes in APD_{90} , $CaTD_{90}$, CaT_{amp} , AT_{peak} and AT_{RT50} (mut vs. ctrl) from [1] were used to guide the optimization process. The final parameter set defining the *c772G>A* mutation is reported in Table 1.

Parameter	SF	Parameter	SF
G_{NaL}	2.4	J_{rel}	0.47
P_{Nab}	2.65	τ_{Caf}	1.35
G_{to}	0.3	τ_{Cas}	1.2
G_{Kr}	0.81	r_{cell}^2	1.9
G_{Ks}	0.55	P_{CaL}	1.02
G_{K1}	0.7	k_{off}	0.8
G_{NCX}	2.15	μ	1.52
P_{NaK}	0.7	J_{up}	0.98

Table 1. Optimized BPS model parameter changes for the MYBPC3-*c772G>A* HCM mutation. SF: scaling factor.

The mutation was applied to the calibrated control population; checks were made on intracellular ionic concentrations ($5 < Na_i < 15$ mM, $0 < Ca_i < 10$ mM), repolarization failures and early after-depolarizations in order to discard cells showing abnormal dynamics.

2.4. Sensitivity analysis

To assess the importance of model parameters in modulating biomarkers and pro-arrhythmicity, a sensitivity analysis was performed. On one hand, a least-square linear regression approach as in [12] was adopted; on the other, logistic regression was performed as in [13] to investigate the influence of the 19 parameters on EADs inducibility. For the latter, the protocols adopted were the same as in [6]: fast pacing for 1500 beats at a basic cycle length (*CL*) of 275 ms followed by a 10 s pause to induce Ca^{2+} overload

for DADs and either 20 μ M quinidine or 0.1 μ M dofetilide administration on top of slow pacing (*CL* = 4000 and 5000 ms, respectively) to elicit EADs. Quinidine administration was simulated by blocking I_{Na} , I_{Kr} , I_{CaL} , I_{Ks} and I_{to} maximal conductances by 59.5%, 98.3%, 86.4%, 87.8% and 90.6%, respectively, according to their IC50 values. Dofetilide was instead simulated by blocking I_{Kr} maximal conductance by 93.8% with altered ionic concentrations ($[K^+]_o = 5$ mM, $[Ca^{2+}]_o = 2$ mM and $[Na^+]_o = 137$ mM). All protocols were applied to the endocardial and mid-myocardial (M cells) versions of the model.

3. Results

Following the population approach described above, we obtained 119 calibrated cells on which we applied the MYBPC3-*c772G>A* mutation. Due to the parameter changes, 11 cells had to be discarded according to the criteria stated in the Methods, remaining with a mutant population of 108 cells. Figure 1 reports AP, CaT and AT traces for the calibrated control, mutated and discarded cell populations.

The analysis of the biomarkers (Figure 2) shows an *APD* prolongation (+63.4%) and an increase in triangulation ($APD_{90}-APD_{40}$: +63.3%) in the mutant population, while the calcium transient is prolonged to a less extent (+13.8% in $CaTD_{90}$) and relaxation times are shorter (−15.8% in RT_{95}). Peak tension is also similar in the two groups (20.4 ± 9 kPa of the mutation vs. 18.9 ± 7 kPa in control), as found experimentally despite the hypertrophic phenotype. The linear regression showed similar results between control and mutant population in terms of biomarkers dependence on model parameters, with $Ca_{50,TRPN}$ having a major role in modulation CaT duration and amplitude and, as a consequence, AT peak.

In terms of DADs inducibility, the control and mutant populations show similar behaviors, with a percentage of 18.3 and 17.3% (endocardial) and 22.3 and 16.9% (M cells), respectively. About EADs, few occurrences were obtained with the endocardial model (0 vs. 2.8% with quinidine and 3.4 vs. 11.1% with dofetilide). However, with M cells, the *c772G>A* showed its arrhythmogenic potential: 49% of the cells showed an arrhythmic behavior (mainly repolarization failures) with quinidine (vs 28.6% in control) and 69% with dofetilide (vs. 37.8%).

4. Discussion and Conclusion

Pioner et al. [1] reported that the MYBPC3-*c772G>A* mutation – which causes an acceleration of the cross-bridge dynamics enhancing tension generation – leads to a compensatory electrophysiological remodeling determining action potential and calcium transient prolongations. As a consequence, the peak in the active tension devel-




Figure 1. Action potential (A), calcium transient (B) and active tension (C) traces of the MYBPC3-c.772G>A population (green) vs. control (blue).

oped by adult ventricular myocytes is similar to healthy control cells due to the slower calcium-handling dynamics. This is reflected in our results with the mutant population (Figures 1 and 2), for which the biomarkers show substantial AP prolongation and a consequent mild calcium transient duration increase, leading to limited increases in active tension (+7.9%). Despite the absence of statistically significant difference, the experiments showed a tendency towards a reduction in the AT peak (−12.6%), possibly suggesting that the model shows less sensitivity to the compensatory mechanism than in vitro myocytes.

Our following analysis suggests that this electrophysiological compensation (as one would expect from the substantial APD prolongation) comes at the cost of an increased risk of arrhythmia, quantified as the occurrence of




Figure 2. Action potential (A), calcium transient (B) and active tension (C) biomarkers (bottom) of the MYBPC3-c.772G>A population (green) vs. control (blue).

early after-depolarizations. Indeed, the reduction of the repolarization reserve due to remodeling determines a higher propensity of mutated cells to show EADs upon further block of I_{Kr} due to dofetilide administration. Considering the limited number of available cells composing the populations, no reliable results could be obtained from the logistic regression with 19 parameters. However, the parameter distributions (Fig 3) show that, in the case of mutant M cells with the dofetilide protocol, the cells showing EADs or RF had higher P_{Ca} and G_{NaL} , slightly higher μ , lower G_{Ks} and τ_{CaF} . Interestingly, cells showing RF had lower J_{up} and G_{NaK} than cells with or without EADs. G_{NaCa} was increased in RF cells but decreased in EADs ones, compared to control.

The limitations of the present work include the small




Figure 3. Action potential (A), calcium transient (B) and active tension (C) biomarkers (bottom) of the MYBPC3-c.772G>A population (green) vs. control (blue).

number of cells of the healthy population that pass the calibration phase. This is due, on one hand, to the restrictive ranges for active tension parameters found experimentally and, on the other, to the sensitivity of the Ca^{2+} -tension curve of the BPS model. Despite this, the number of calibrated cells we obtained ($n = 119/10000$) is still large enough to allow comparison between healthy and mutant populations. In conclusion, our analysis could guide pharmacological interventions to reduce the increased arrhythmic risk of the MYBPC3-c.772G>A mutation, pointing to a reduction in L-type calcium or late sodium currents, as well as an increase in SERCA uptake rate or Na^+/K^+ pump current to avoid repolarization failures. On the opposite, based on this results one could act on enhancing the sodium-potassium pump, the rapid delayed rectifier currents or increasing of the SERCA uptake rate. In general, the population of model approach adopted in the present study can provide useful information in the effort towards mutation-specific stratification of different HCM variants.

Acknowledgments

E.R., F.M., A.F. and S.S. were funded by the European Union - Project 101137115 — SMASH-HCM. C.B. and S.S. have received funding from the European Union - NextGenerationEU through the Italian Ministry of University and Research under PNRR - M4C2-I1.3 Project PR_00000019 “HEAL ITALIA” to S.S. CUP J33C22002920006.

References

- [1] Pioner JM, Vitale G et al. Slower calcium handling balances faster cross-bridge cycling in human β_1 mybpc3/i_h hcm. *Circulation Research* 2023;132(5):628–644.
- [2] Steczina S, Mohran S et al. Mybpc3-c.772g>a mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy. *Journal of Molecular and Cellular Cardiology* 2024;191:27–39. ISSN 0022-2828.
- [3] Coppini R, Ferrantini C et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. *Circulation* 2013;127(5):575–584.
- [4] Passini E, Mincholé A et al. Mechanisms of proarrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy. *Journal of Molecular and Cellular Cardiology* 2016; 96:72–81. ISSN 0022-2828. Special Issue: Computational Modelling of the Heart.
- [5] Coleman JA, Doste R et al. Mechanisms of ischaemia-induced arrhythmias in hypertrophic cardiomyopathy: a large-scale computational study. *Cardiovascular Research* 04 2024;120(8):914–926. ISSN 0008-6363.
- [6] Bartolucci C, Forouzandehmehr M et al. A novel in silico electromechanical model of human ventricular cardiomyocyte. *Frontiers in Physiology* 2022;13. ISSN 1664-042X.
- [7] Tomek J, Bueno-Orovio A et al. Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block. *eLife* dec 2019; 8:e48890. ISSN 2050-084X.
- [8] Bartolucci C, Passini E et al. Simulation of the effects of extracellular calcium changes leads to a novel computational model of human ventricular action potential with a revised calcium handling. *Frontiers in Physiology* 2020;11. ISSN 1664-042X.
- [9] Land S, Park-Holohan SJ et al. A model of cardiac contraction based on novel measurements of tension development in human cardiomyocytes. *Journal of Molecular and Cellular Cardiology* 2017;106:68–83. ISSN 0022-2828.
- [10] Paci M, Passini E et al. All-optical electrophysiology refines populations of in silico human ipsc-cms for drug evaluation. *Biophysical Journal* 2020;118(10):2596–2611. ISSN 0006-3495.
- [11] Mora MT, Zaza A, Trenor B. Insights from an electromechanical heart failure cell model: Role of serca enhancement on arrhythmogenesis and myocyte contraction. *Computer Methods and Programs in Biomedicine* 2023; 230:107350. ISSN 0169-2607.
- [12] Morotti S, Nieves-Cintrón M et al. Predominant contribution of l-type cav1.2 channel stimulation to impaired intracellular calcium and cerebral artery vasoconstriction in diabetic hyperglycemia. *Channels* 2017;11(4):340–346. PMID: 28631947.
- [13] Morotti S, Grandi E. Logistic regression analysis of populations of electrophysiological models to assess proarrhythmic risk. *MethodsX* 2017;4:25–34. ISSN 2215-0161.

Address for correspondence:

Eugenio Ricci
Department of Electrical, Electronic and Information Engineering, University of Bologna
Via dell'Università 50, 47522 Cesena (FC), Italy
eugenio.ricci3@unibo.it